Viewing Study NCT05545969

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 11:02 PM
Ignite Modification Date: 2026-05-23 @ 12:26 PM
Study NCT ID: NCT05545969
Status: WITHDRAWN
Last Update Posted: 2024-06-26
First Post: 2022-09-06
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Neoadjuvant Pembrolizumab and Lenvatinib for Mucosal Melanoma
Sponsor: Melanoma Institute Australia
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Mucosal Melanoma View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Immunotherapy View
None VEGF inhibitor View
None Neoadjuvant View
None Adjuvant View
None Pembrolizumab View
None Lenvatinib View
None Pathlogical respone View